

Steven Joniau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8710819/publications.pdf>

Version: 2024-02-01

557
papers

24,735
citations

13827

67
h-index

8370

147
g-index

606
all docs

606
docs citations

606
times ranked

21590
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	0.9	2,497
2	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intentâ€™ Update 2013. <i>European Urology</i> , 2014, 65, 124-137.	0.9	1,613
3	EAU Guidelines on Prostate Cancer. <i>European Urology</i> , 2008, 53, 68-80.	0.9	1,373
4	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 467-479.	0.9	1,304
5	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. <i>European Urology</i> , 2011, 59, 61-71.	0.9	1,299
6	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	0.9	1,215
7	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 446-453.	0.8	972
8	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
9	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2011, 59, 572-583.	0.9	459
10	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 84-109.	0.9	348
11	Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. <i>International Journal of Cancer</i> , 2002, 98, 19-22.	2.3	320
12	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , 2017, 72, 250-266.	0.9	305
13	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
14	Radiotherapy for renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2014, 15, e170-e177.	5.1	226
15	Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. <i>European Urology</i> , 2010, 57, 466-473.	0.9	225
16	Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. <i>European Urology</i> , 2013, 63, 450-458.	0.9	216
17	Selective activation of the fatty acid synthesis pathway in human prostate cancer. <i>International Journal of Cancer</i> , 2000, 88, 176-179.	2.3	207
18	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. <i>BJU International</i> , 2010, 106, 462-469.	1.3	207

#	ARTICLE	IF	CITATIONS
19	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2014, 15, e404-e414.	5.1	196
20	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	0.9	190
21	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>European Urology</i> , 2016, 70, 161-175.	0.9	184
22	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	0.9	182
23	Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design. <i>European Urology</i> , 2014, 65, 1078-1083.	0.9	180
24	Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. <i>European Urology</i> , 2015, 67, 157-164.	0.9	180
25	Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. <i>European Urology</i> , 2011, 60, 205-210.	0.9	175
26	Early Salvage Radiotherapy Following Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1034-1043.	0.9	171
27	Contemporary Management of Small Renal Masses. <i>European Urology</i> , 2011, 60, 501-515.	0.9	164
28	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. <i>European Urology</i> , 2012, 62, 472-487.	0.9	157
29	Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. <i>European Urology</i> , 2007, 51, 121-129.	0.9	152
30	Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 1392-1401.	1.9	150
31	Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases. <i>European Urology</i> , 2011, 60, 125-130.	0.9	142
32	Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. <i>European Urology</i> , 2010, 58, 1-7.	0.9	140
33	Comparison between Open Partial and Radical Nephrectomy for Renal Tumours: Perioperative Outcome and Health-Related Quality of Life. <i>European Urology</i> , 2007, 51, 614-620.	0.9	135
34	Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine Samples. <i>European Urology</i> , 2010, 58, 96-104.	0.9	134
35	High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. <i>Journal of Pathology</i> , 2005, 206, 214-219.	2.1	127
36	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	0.9	121

#	ARTICLE	IF	CITATIONS
37	Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. <i>BJU International</i> , 2011, 107, 765-770.	1.3	120
38	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	0.9	119
39	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	1.6	116
40	Androgen Regulation of the TMPRSS2 Gene and the Effect of a SNP in an Androgen Response Element. <i>Molecular Endocrinology</i> , 2013, 27, 2028-2040.	3.7	113
41	Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer. <i>European Urology</i> , 2012, 61, 584-592.	0.9	112
42	The impact of retransurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. <i>BJU International</i> , 2016, 118, 44-52.	1.3	110
43	Survival in Patients with High-Risk Prostate Cancer Is Predicted by miR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3. <i>Cancer Research</i> , 2014, 74, 2591-2603.	0.4	107
44	Emerging mechanisms of enzalutamide resistance in prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 712-716.	1.9	107
45	Surveillance or metastasis-directed Therapy for Oligometastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2014, 14, 671.	1.1	106
46	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 68-91.	2.0	105
47	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	0.9	102
48	An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer. <i>European Urology</i> , 2008, 53, 253-259.	0.9	101
49	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e7-163.e13.	0.8	101
50	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	0.9	101
51	Identification of telocytes in the upper lamina propria of the human urinary tract. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2085-2093.	1.6	100
52	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 66, 191-199.	0.9	100
53	Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. <i>BJU International</i> , 2008, 101, 5-10.	1.3	98
54	Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2013, 63, 693-701.	0.9	98

#	ARTICLE	IF	CITATIONS
55	Small renal mass biopsy – how, what and when: report from an international consensus panel. BJU International, 2014, 113, 854-863.	1.3	98
56	Survival and Impact of Clinical Prognostic Factors in Surgically Treated Metastatic Renal Cell Carcinoma. European Urology, 2013, 63, 646-652.	0.9	89
57	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
58	Influence of Preoperative and Postoperative Pelvic Floor Muscle Training (PFMT) Compared with Postoperative PFMT on Urinary Incontinence After Radical Prostatectomy: A Randomized Controlled Trial. European Urology, 2013, 64, 766-772.	0.9	86
59	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.. Journal of Clinical Oncology, 2020, 38, 10-10.	0.8	82
60	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 2020, 38, 4064-4075.	0.8	78
61	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	0.9	77
62	Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial – NIMBUS. European Urology, 2020, 78, 690-698.	0.9	76
63	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. European Urology, 2016, 69, 802-820.	0.9	75
64	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	0.9	74
65	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. Molecular Cancer Therapeutics, 2016, 15, 1702-1712.	1.9	73
66	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480.	0.9	72
67	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology, 2006, 17, 1185-1196.	0.6	68
68	Distinct microRNA Expression Profile in Prostate Cancer Patients with Early Clinical Failure and the Impact of let-7 as Prognostic Marker in High-Risk Prostate Cancer. PLoS ONE, 2013, 8, e65064.	1.1	68
69	Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU International, 2014, 114, 81-89.	1.3	68
70	Current Status of Minimally Invasive Ablative Techniques in the Treatment of Small Renal Tumours. European Urology, 2007, 51, 328-336.	0.9	67
71	Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e23-109.e31.	0.8	63
72	Phase 2 Study of ^{99m} Tc-Trofolostat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. Journal of Nuclear Medicine, 2017, 58, 1408-1413.	2.8	63

#	ARTICLE	IF	CITATIONS
73	Vaccine Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 1333-1344.	0.9	62
74	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. <i>Journal of Urology</i> , 2019, 202, 725-731.	0.2	62
75	A Possible Role for MicroRNA-141 Down-Regulation in Sunitinib Resistant Metastatic Clear Cell Renal Cell Carcinoma Through Induction of Epithelial-to-Mesenchymal Transition and Hypoxia Resistance. <i>Journal of Urology</i> , 2013, 189, 1930-1938.	0.2	61
76	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	0.9	60
77	Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. <i>European Urology Oncology</i> , 2019, 2, 174-188.	2.6	58
78	Is Surveillance an Option for the Treatment of Small Renal Masses?. <i>European Urology</i> , 2007, 52, 1323-1330.	0.9	57
79	Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy. <i>BJU International</i> , 2013, 112, 936-943.	1.3	57
80	Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. <i>European Journal of Radiology</i> , 2012, 81, e217-e222.	1.2	55
81	A Pretreatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer. <i>European Urology</i> , 2007, 51, 388-396.	0.9	54
82	Outcome of nephron-sparing surgery for T1b renal cell carcinoma. <i>BJU International</i> , 2009, 103, 1344-1348.	1.3	53
83	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	0.8	53
84	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. <i>BJU International</i> , 2017, 120, 815-821.	1.3	53
85	Comparing the rules of engagement of androgen and glucocorticoid receptors. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2217-2228.	2.4	51
86	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	3.4	50
87	Metabolic Changes after Urinary Diversion. <i>Advances in Urology</i> , 2011, 2011, 1-5.	0.6	49
88	Adipose-derived Stem Cells Counteract Urethral Stricture Formation in Rats. <i>European Urology</i> , 2016, 70, 1032-1041.	0.9	49
89	Clinical Experience with the N-shaped Ileal Neobladder: Assessment of Complications, Voiding Patterns, and Quality of Life in Our Series of 58 Patients. <i>European Urology</i> , 2005, 47, 666-673.	0.9	44
90	Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1486-1492.	0.4	44

#	ARTICLE	IF	CITATIONS
91	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , 2019, 9, 13786.	1.6	44
92	Pelvic Exenterations for Gynecological Malignancies. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 889-896.	1.2	42
93	MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 21414-21434.	1.8	42
94	Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2003, 6, 305-310.	2.0	41
95	Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 141-146.	0.8	41
96	Segmental Testicular Infarction: Conservative Management is Feasible and Safe. <i>European Urology</i> , 2008, 53, 441-445.	0.9	40
97	Quality Control Indicators for Transurethral Resection of Nonâ€“Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e784-e792.	0.9	40
98	Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 305-309.	2.6	40
99	Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. <i>Urology</i> , 2006, 67, 199.e17-199.e19.	0.5	39
100	Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. <i>World Journal of Urology</i> , 2013, 31, 1073-1080.	1.2	39
101	Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. <i>Radiation Oncology</i> , 2007, 2, 29.	1.2	38
102	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	1.9	38
103	The indications for partial nephrectomy in the treatment of renal cell carcinoma. <i>Nature Reviews Urology</i> , 2006, 3, 198-205.	1.4	37
104	A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. <i>Radiotherapy and Oncology</i> , 2010, 97, 474-479.	0.3	37
105	Radical prostatectomy in very high-risk localized prostate cancer: Long-term outcomes and outcome predictors. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 164-171.	1.4	37
106	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	0.9	37
107	Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathy. <i>Nature Reviews Urology</i> , 2007, 4, 455-458.	1.4	36
108	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	0.9	36

#	ARTICLE	IF	CITATIONS
109	Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy. EAU Update Series, 2005, 3, 90-97.	0.5	35
110	Current Vaccination Strategies for Prostate Cancer. European Urology, 2012, 61, 290-306.	0.9	35
111	The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making. BioMed Research International, 2014, 2014, 1-16.	0.9	35
112	Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines. PLoS ONE, 2014, 9, e90002.	1.1	35
113	Idiopathic Partial Thrombosis of the Corpus Caverosum: Conservative Management Is Effective and Possible. European Urology, 2003, 44, 119-123.	0.9	34
114	Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. Clinical Genitourinary Cancer, 2014, 12, e205-e214.	0.9	33
115	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget, 2016, 7, 24326-24338.	0.8	33
116	Continent catheterizable vesicostomy in an adult population: Success at high costs. Neurourology and Urodynamics, 2009, 28, 487-491.	0.8	32
117	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. Journal of Urology, 2020, 204, 296-302.	0.2	32
118	Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. European Journal of Cancer, 2007, 43, 1694-1700.	1.3	31
119	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1849-1861.	1.2	31
120	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncologica, 2014, 53, 1413-1422.	0.8	30
121	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE, 2015, 10, e0130651.	1.1	30
122	Detection of clinical unilateral T3a prostate cancer ? by digital rectal examination or transrectal ultrasonography?. BJU International, 2006, 98, 982-985.	1.3	29
123	Debulking surgery in the setting of very high-risk prostate cancer scenarios. BJU International, 2012, 110, E192-8.	1.3	29
124	Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy. Current Opinion in Oncology, 2014, 26, 514-520.	1.1	29
125	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World Journal of Urology, 2018, 36, 1621-1627.	1.2	29
126	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. European Urology Oncology, 2020, 3, 73-79.	2.6	29

#	ARTICLE	IF	CITATIONS
127	Effect of Nutritional Supplement Challenge in Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia. <i>Urology</i> , 2007, 69, 1102-1106.	0.5	28
128	Evaluating a Decision Aid for Patients with Localized Prostate Cancer in Clinical Practice. <i>Urologia Internationalis</i> , 2008, 81, 383-388.	0.6	28
129	Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. <i>Journal of Urology</i> , 2012, 188, 84-90.	0.2	28
130	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, R545-R557.	1.6	28
131	Prostatic Intraepithelial Neoplasia (PIN): Importance and Clinical Management. <i>European Urology</i> , 2005, 48, 379-385.	0.9	27
132	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	0.9	27
133	Metanephric adenoma during pregnancy: clinical presentation, histology, and cytogenetics. <i>Human Pathology</i> , 2006, 37, 1227-1232.	1.1	26
134	How Important Are Surgical Margins in Nephron-Sparing Surgery?. <i>European Urology Supplements</i> , 2007, 6, 533-539.	0.1	26
135	Elective nodal radiotherapy in prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, e348-e357.	5.1	26
136	Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy. <i>BJU International</i> , 2007, 99, 311-314.	1.3	25
137	Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). <i>BJU International</i> , 2008, 101, 444-449.	1.3	25
138	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 673-683.	0.9	25
139	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015, 26, 2392-2398.	0.6	25
140	Hypofractionated palliative radiotherapy for bladder cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 181-186.	1.0	25
141	Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery. <i>Prostate Cancer and Prostatic Diseases</i> , 2003, 6, 61-65.	2.0	24
142	Polypoid endometriosis of the bladder during pregnancy mimicking urachal carcinoma. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 475-478.	0.9	24
143	Idiopathic partial thrombosis of the corpus cavernosum: Aetiology, diagnosis and treatment. <i>Scandinavian Journal of Urology</i> , 2013, 47, 163-168.	0.6	24
144	The Genomic Landscape of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 10822-10851.	1.8	24

#	ARTICLE	IF	CITATIONS
145	Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncologica</i> , 2015, 54, 896-902.	0.8	24
146	Intratumoral Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease. <i>Sexual Medicine</i> , 2019, 7, 94-103.	0.9	24
147	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 296.e21-296.e29.	0.8	24
148	Complications and Functional Results of Surgery for Locally Advanced Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-8.	0.6	23
149	Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro. <i>Molecular and Cellular Endocrinology</i> , 2016, 437, 280-291.	1.6	23
150	Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.	1.3	23
151	The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 407-412.	2.0	23
152	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1857-1866.	1.2	23
153	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1211-1218.	3.3	23
154	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	2.6	23
155	Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 31-37.	2.0	22
156	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	1.2	22
157	Preclinical Evidence for the Benefits of Penile Rehabilitation Therapy following Nerve-Sparing Radical Prostatectomy. <i>Advances in Urology</i> , 2008, 2008, 1-10.	0.6	21
158	Is there a prostate-specific antigen upper limit for radical prostatectomy?. <i>BJU International</i> , 2011, 108, 1093-1100.	1.3	21
159	Renal Cell Carcinoma with Synchronous Metastasis to the Calcaneus and Metachronous Metastases to the Ovary and Gallbladder. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.3	20
160	Results of surgery for high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 342-348.	0.9	20
161	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 110, 45-54.	0.3	20
162	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. <i>British Journal of Cancer</i> , 2015, 113, 1313-1322.	2.9	19

#	ARTICLE	IF	CITATIONS
163	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Frontiers in Surgery</i> , 2016, 3, 65.	0.6	19
164	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	2.6	19
165	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. <i>Urology</i> , 2019, 130, 113-119.	0.5	19
166	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1543-1549.	1.2	19
167	Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. <i>Journal of Urology</i> , 2019, 201, 315-321.	0.2	19
168	Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. <i>BMC Urology</i> , 2012, 12, 8.	0.6	18
169	Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. <i>Cancers</i> , 2020, 12, 2271.	1.7	18
170	Kidney Radiofrequency Ablation for Small Renal Tumors: Oncologic Efficacy. <i>Journal of Endourology</i> , 2010, 24, 721-728.	1.1	17
171	Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLadder cancer Trial. <i>European Journal of Cancer</i> , 2016, 69, 9-18.	1.3	17
172	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , 2018, 4, 369-375.	1.6	17
173	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , 2019, 75, 817-825.	0.9	17
174	Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 512-526.	1.3	17
175	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 960-967.	0.4	16
176	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 333-340.	0.4	16
177	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. <i>BMC Cancer</i> , 2018, 18, 354.	1.1	16
178	Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. <i>World Journal of Urology</i> , 2019, 37, 1507-1515.	1.2	16
179	Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. <i>World Journal of Urology</i> , 2020, 39, 2545-2552.	1.2	16
180	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16

#	ARTICLE	IF	CITATIONS
181	Luteinizing hormone-releasing hormone (<scp>LHRH</scp>) receptor agonists vs antagonists: a matter of the receptors?. <i>BJU International</i> , 2013, 111, 1021-1030.	1.3	15
182	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 234.e13-234.e19.	0.8	15
183	The role of TET-mediated DNA hydroxymethylation in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 41-55.	1.6	15
184	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , 2018, 36, 1775-1781.	1.2	15
185	Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. <i>European Urology</i> , 2020, 78, 820-821.	0.9	15
186	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. <i>Translational Andrology and Urology</i> , 2020, 9, 2541-2554.	0.6	15
187	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
188	Results of buccal mucosa grafts for repairing long bulbar urethral strictures. <i>BJU International</i> , 2010, 105, 1170-1172.	1.3	14
189	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 565-579.	0.2	14
190	Sense and Nonsense of an Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-6.	0.6	14
191	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 319-325.	0.9	14
192	Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1367-1372.	1.2	14
193	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	4.3	14
194	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	0.9	14
195	Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease. <i>BJU International</i> , 2019, 124, 342-348.	1.3	14
196	Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 501-511.	1.3	14
197	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> , 2022, 150, 837-846.	2.3	14
198	Open Surgery for Localized RCC. <i>Scientific World Journal, The</i> , 2007, 7, 742-752.	0.8	13

#	ARTICLE	IF	CITATIONS
199	PCA: Prostate Cancer, Patient-Centred Approach or both?. <i>BJU International</i> , 2012, 110, 16-22.	1.3	13
200	Characterization of subepithelial interstitial cells in normal and pathological human prostate. <i>Histopathology</i> , 2014, 65, 418-428.	1.6	13
201	Idiopathic Partial Thrombosis (IPT) of the Corpus Cavernosum: A Hypothesis-Generating Case Series and Review of the Literature. <i>Journal of Sexual Medicine</i> , 2015, 12, 2118-2125.	0.3	13
202	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	0.9	13
203	Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy. <i>European Urology Oncology</i> , 2019, 2, 110-117.	2.6	13
204	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 2494.	1.8	13
205	Salvage Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 156-162.	0.6	13
206	A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence. <i>BJU International</i> , 2021, 127, 575-584.	1.3	13
207	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	1.6	13
208	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. <i>Practical Radiation Oncology</i> , 2021, 11, 202-211.	1.1	13
209	Bilateral renal cell carcinoma development in long-term Fabry disease. <i>Journal of Inherited Metabolic Disease</i> , 2007, 30, 830-831.	1.7	12
210	The Motion: Nomograms Should Become a Routine Tool in Determining Prostate Cancer Prognosis. <i>European Urology</i> , 2009, 55, 743-747.	0.9	12
211	Ablative therapies in the treatment of small renal tumors: How far from standard of care?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 251-259.	0.8	12
212	Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 789-795.	1.0	12
213	Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. <i>Acta Oncologica</i> , 2013, 52, 1336-1344.	0.8	12
214	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	1.6	12
215	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 493-499.	0.6	12
216	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 41.	1.1	12

#	ARTICLE	IF	CITATIONS
217	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	0.8	12
218	The Use of IIEF-5 for Reporting Erectile Dysfunction Following Nerve-Sparing Radical Retropubic Prostatectomy. <i>The Open Prostate Cancer Journal</i> , 2009, 2, 1-9.	0.4	12
219	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11256.	0.5	12
220	Tumour-related imaging parameters predicting the percentage of preserved normal renal parenchyma following nephron sparing surgery: a retrospective study. <i>European Radiology</i> , 2013, 23, 280-286.	2.3	11
221	What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. <i>Current Urology Reports</i> , 2015, 16, 70.	1.0	11
222	Endovascular Management of Severe Arterial Haemorrhage After Radical Prostatectomy: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1698-1705.	0.9	11
223	Open and robotic radical prostatectomy. <i>Asian Journal of Urology</i> , 2019, 6, 125-128.	0.5	11
224	Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis. <i>International Journal of Impotence Research</i> , 2020, 32, 281-288.	1.0	11
225	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 246.	1.3	11
226	Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer. <i>Cancers</i> , 2021, 13, 915.	1.7	11
227	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. <i>European Radiology</i> , 2022, 32, 901-911.	2.3	11
228	The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. <i>PLoS ONE</i> , 2020, 15, e0244663.	1.1	11
229	Open Surgical Treatment of Localised Renal Cell Cancer. <i>EAU Update Series</i> , 2003, 1, 220-225.	0.5	10
230	Prepubic Urethrectomy during Radical Cystoprostatectomy. <i>European Urology</i> , 2007, 51, 915-921.	0.9	10
231	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. <i>SpringerPlus</i> , 2016, 5, 646.	1.2	10
232	Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients. <i>American Journal of Pathology</i> , 2018, 188, 795-804.	1.9	10
233	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 781.e17-781.e24.	0.8	10
234	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	10

#	ARTICLE	IF	CITATIONS
235	Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. <i>Annals of Oncology</i> , 2019, 30, v891-v892.	0.6	10
236	Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection. <i>Journal of Urology</i> , 2020, 203, 713-718.	0.2	10
237	Metastasectomy of oligometastatic urothelial cancer: a single-center experience. <i>Translational Andrology and Urology</i> , 2020, 9, 1296-1305.	0.6	10
238	Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9522-32.	0.5	10
239	Salvage Radical Prostatectomy in Nonmetastatic Castration-resistant Prostate Cancer Patients Who Received Previous Radiotherapy: A Feasibility Study. <i>European Urology</i> , 2014, 65, 254-255.	0.9	9
240	Nephron Sparing for Renal Cell Carcinoma: Whenever Possible?. <i>European Urology Focus</i> , 2016, 2, 656-659.	1.6	9
241	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 280.	1.3	9
242	Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series. <i>European Urology Oncology</i> , 2018, 1, 338-345.	2.6	9
243	Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?. <i>European Urology</i> , 2019, 76, 265-267.	0.9	9
244	Impact of the 2014 International Society of Urological Pathology Grading System on Concept of High-Risk Prostate Cancer: Comparison of Long-Term Oncological Outcomes in Patients Undergoing Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2019, 9, 1272.	1.3	9
245	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3337-3344.	1.2	9
246	Impact of Grade Groups on Prostate Cancer-Specific and Other-Cause Mortality: Competing Risk Analysis from a Large Single Institution Series. <i>Cancers</i> , 2021, 13, 1963.	1.7	9
247	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	0.9	9
248	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782.	0.8	9
249	The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis. <i>Advances in Urology</i> , 2012, 2012, 1-6.	0.6	8
250	Active surveillance for small renal tumors: Have clinical concerns been addressed so far?. <i>International Journal of Urology</i> , 2013, 20, 356-361.	0.5	8
251	Implementing newer agents for the management of castration-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015, 115, 364-372.	1.3	8
252	Oligometastatic prostate cancer: Metastases-directed therapy?. <i>Arab Journal of Urology Arab Association of Urology</i> , 2016, 14, 179-182.	0.7	8

#	ARTICLE	IF	CITATIONS
253	Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. <i>Acta Oncologica</i> , 2016, 55, 329-340.	0.8	8
254	Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. <i>Cancer</i> , 2017, 123, 4139-4146.	2.0	8
255	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , 2017, 77, 3-9.	1.2	8
256	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. <i>European Urology Oncology</i> , 2022, 5, 587-600.	2.6	8
257	Patient-reported outcomes after buccal mucosal graft urethroplasty for bulbar urethral strictures: results of a prospective single-centre cohort study. <i>BJU International</i> , 2020, 126, 684-693.	1.3	8
258	Prophylactic ureteral catheterization in the intraoperative diagnosis of iatrogenic ureteral injury. <i>Acta Chirurgica Belgica</i> , 2021, 121, 261-266.	0.2	8
259	Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. <i>Journal of Clinical Medicine</i> , 2021, 10, 999.	1.0	8
260	Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study. <i>Psycho-Oncology</i> , 2022, 31, 219-226.	1.0	8
261	Segmental Testicular Infarction: Conservative Management is Feasible and Safe: Part 2. <i>European Urology</i> , 2008, 53, 656-658.	0.9	7
262	Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 116-123.	2.0	7
263	Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 131-137.	0.8	7
264	Pseudoaneurysm Associated With an Arteriovesical Fistula After Bladder Substitution Surgery Definitively Treated With a Covered Stent. <i>Vascular and Endovascular Surgery</i> , 2013, 47, 652-655.	0.3	7
265	Evaluation of conservative approach in the management of ureteroenteric strictures following radical cystectomy with Bricker ileal conduit: a single-center experience. <i>Scandinavian Journal of Urology</i> , 2016, 50, 439-444.	0.6	7
266	Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy. <i>European Urology Focus</i> , 2018, 4, 288-293.	1.6	7
267	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 781.	1.3	7
268	Excision and Primary Anastomosis for Bulbar Urethral Strictures Improves Functional Outcomes and Quality of Life: A Prospective Analysis from a Single Centre. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	7
269	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	1.3	7
270	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. <i>Cancers</i> , 2020, 12, 132.	1.7	7

#	ARTICLE	IF	CITATIONS
271	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 3177-3185.	1.2	7
272	Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7890-7900.	1.6	7
273	Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. <i>BMC Cancer</i> , 2020, 20, 457.	1.1	7
274	External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. <i>Central European Journal of Urology</i> , 2020, 73, 19-25.	0.2	7
275	Selective Mass Spectrometry Imaging of Aromatic Antioxidants Using Sequential Matrix-Assisted Laser Desorption and Resonant Photoionisation. <i>Analysis & Sensing</i> , 2022, 2, .	1.1	7
276	Prepubic urethrectomy. <i>BJU International</i> , 2009, 103, 118-132.	1.3	6
277	What Is the Contemporary Role of Radiofrequency Ablation in the Management of Small Renal Masses? Are Small Lesions the Radiologist's Tumors?. <i>European Urology</i> , 2013, 63, 493-495.	0.9	6
278	Controversies on individualized prostate cancer care: gaps in current practice. <i>Therapeutic Advances in Urology</i> , 2013, 5, 233-244.	0.9	6
279	Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. <i>BJU International</i> , 2017, 120, E52-E58.	1.3	6
280	Prostate Cancer and the John West Effect. <i>European Urology</i> , 2017, 72, 7-9.	0.9	6
281	Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 84-90.	0.8	6
282	Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer. <i>Current Urology</i> , 2017, 10, 217-220.	0.4	6
283	Successful Perioperative and Surgical Treatment of a Rare Case of Extra-Gastrointestinal Stromal Tumor Arising in the Prostate Gland. <i>Case Reports in Oncology</i> , 2019, 12, 183-191.	0.3	6
284	Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium. <i>Pathology and Oncology Research</i> , 2020, 26, 2605-2612.	0.9	6
285	Surgical management of acquired rectourethral fistula: a retrospective analysis of 52 consecutive patients. <i>Techniques in Coloproctology</i> , 2020, 24, 927-933.	0.8	6
286	Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 78-85.	0.7	6
287	Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer. <i>PLoS ONE</i> , 2021, 16, e0257195.	1.1	6
288	Validation of an Improved Patient-Specific Mold Design for Registration of In-vivo MRI and Histology of the Prostate. <i>Lecture Notes in Computer Science</i> , 2016, , 36-43.	1.0	6

#	ARTICLE	IF	CITATIONS
289	Een beslissingshulp voor patiënten met gelokaliseerde prostaatkanker: eerste resultaten. Tijdschrift Voor Geneeskunde, 2007, 63, 15-21.	0.0	6
290	A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 940-950.	0.9	6
291	Urachal carcinoma during pregnancy. Urology, 2006, 67, 1290.e19-1290.e21.	0.5	5
292	Radical Prostatectomy for PSA \leq 100ng/ml Prostate Cancer. European Urology, 2008, 54, 957-958.	0.9	5
293	EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urológicas Españolas (English Edition), 2011, 35, 501-514.	0.2	5
294	Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 37.e11-37.e20.	0.8	5
295	Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 937.e1-937.e9.	0.8	5
296	Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience, 2020, 14, 1036.	0.6	5
297	Surveillance as an Option for the Treatment of Small Renal Masses. Advances in Urology, 2008, 2008, 1-6.	0.6	4
298	Open Radical Prostatectomy. , 2012, , 93-103.		4
299	Positive Surgical Margin at Radical Prostatectomy: Futile or Surgeon-dependent Predictor of Prostate Cancer Death?. European Urology, 2013, 64, 26-28.	0.9	4
300	772 SALVAGE LYMPH NODE DISSECTION FOR PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH BIOCHEMICAL RECURRENCE AND IMAGING-DETECTED NODAL METASTASES. Journal of Urology, 2013, 189, .	0.2	4
301	Caveat Emptor. European Urology, 2014, 66, 673-675.	0.9	4
302	An unusual perineal mass in a male cyclist. International Urology and Nephrology, 2016, 48, 371-372.	0.6	4
303	Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial. World Journal of Urology, 2017, 35, 721-728.	1.2	4
304	Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. Scientific Reports, 2018, 8, 14326.	1.6	4
305	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	1.3	4
306	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. Journal of Clinical Medicine, 2020, 9, 3306.	1.0	4

#	ARTICLE	IF	CITATIONS
307	Prostate-Specific Antigen Modulatory Effect of a Fermented Soy Supplement for Patients with an Elevated Risk of Prostate Cancer: a Non-Randomized, Retrospective Observational Registration. <i>Current Urology</i> , 2020, 14, 142-149.	0.4	4
308	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. <i>World Journal of Urology</i> , 2021, 39, 399-406.	1.2	4
309	Risk stratification tools in prostate cancer, where do we stand?. <i>Translational Andrology and Urology</i> , 2021, 10, 12-18.	0.6	4
310	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
311	Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 153-153.	0.8	4
312	Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. <i>Kidney Cancer</i> , 2020, 4, 177-183.	0.2	4
313	127 The development and evaluation of a decision aid in the treatment of patients with localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2006, 78, S41.	0.3	3
314	RADICAL PROSTATECTOMY FOR LOCALLY ADVANCED PROSTATE cancer with psa \leq 20 ng/ml. <i>European Urology Supplements</i> , 2008, 7, 103.	0.1	3
315	A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2009, 2009, 1-4.	0.3	3
316	MP-02.06: Erectile function after end-to-end repair, buccal mucosa roof strip augmented anastomosis or dorsal-inlay buccal mucosa graft urethroplasty for single-stage bulbar urethroplasty. <i>Urology</i> , 2010, 76, S17.	0.5	3
317	Renal Neoplasm During Pregnancy: A Single Center Experience. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e501-e507.	0.9	3
318	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages \leq cT1b: a single institution, matched analysis. <i>Central European Journal of Urology</i> , 2018, 71, 48-57.	0.2	3
319	No survival difference between super extended and standard lymph node dissection at radical cystectomy: what can we learn from the first prospective randomized phase III trial?. <i>Translational Andrology and Urology</i> , 2019, 8, S112-S115.	0.6	3
320	Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System. <i>Frontiers in Oncology</i> , 2019, 9, 1402.	1.3	3
321	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	1.1	3
322	Guía de la EAU para el Cáncer de Próstata. <i>Actas Urológicas Españolas</i> , 2009, 33, .	0.3	3
323	Long-term consequences of bilateral cavernous crush injury in normal and diabetic rats: a functional study. <i>International Journal of Impotence Research</i> , 2022, 34, 781-785.	1.0	3
324	Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , 2022, 39, 518-531.	1.3	3

#	ARTICLE	IF	CITATIONS
325	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 527-541.	1.5	3
326	Open partial nephrectomy for complex tumours and >4 cm: Is it still the gold standard technique in the minimally invasive era?. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 129-38.	0.1	3
327	Current role of surgery for high risk prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 259-73, 259-74.	0.1	3
328	Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. <i>World Journal of Urology</i> , 0, , .	1.2	3
329	Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5025-5025.	0.8	3
330	Benign renal mesenchymoma in the pediatric age group: a novel pathologic and karyotype entity. <i>Urology</i> , 2004, 63, 981-984.	0.5	2
331	Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation?. <i>Future Oncology</i> , 2007, 3, 515-519.	1.1	2
332	THE VALUE OF THE PCA3 SCORE IN GUIDING PROSTATE BIOPSY DECISION IN MEN WITH A PRIOR NEGATIVE BIOPSY. <i>European Urology Supplements</i> , 2008, 7, 142.	0.1	2
333	IMPORTANCE OF THE LEARNING CURVE IN REDUCING POSITIVE SURGICAL MARGIN RATE AND IMPROVING BIOCHEMICAL PROGRESSION FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR CT3A PROSTATE CANCER. <i>European Urology Supplements</i> , 2008, 7, 167.	0.1	2
334	Re: Bianco FJ, Scardino PT, and Eastham JA: Radical Prostatectomy: Long-term Cancer Control and Recovery of Sexual and Urinary Function (â€œTrifectaâ€) (Urology 66(5 suppl): 83â€“94, 2005). <i>Urology</i> , 2008, 71, 361.	0.5	2
335	RADICAL PROSTATECTOMY IN VERY HIGH RISK LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2009, 181, 576.	0.2	2
336	686 THE ROLE OF ADJUVANT HORMONAL TREATMENT AFTER SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER-RESULTS OF A MULTI-INSTITUTIONAL MATCHED ANALYSIS. <i>European Urology Supplements</i> , 2010, 9, 225.	0.1	2
337	471 THE NUMBER OF POSITIVE SECTION MARGINS IN HIGH-RISK PROSTATE CANCER IS A POWERFUL AND INDEPENDENT PREDICTOR OF CANCER-SPECIFIC AND OVERALL SURVIVAL IN HIGH-RISK LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2011, 185, .	0.2	2
338	Nodal Staging in Prostate Cancer: Still an Unresolved Issue. <i>European Urology</i> , 2012, 61, 1139-1141.	0.9	2
339	Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions. <i>Drugs and Aging</i> , 2013, 30, 877-886.	1.3	2
340	18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study. <i>EJNMMI Research</i> , 2013, 3, 59.	1.1	2
341	963 DEVELOPMENT AND INTERNAL VALIDATION OF A NOMOGRAM PREDICTING BIOCHEMICAL RECURRENCE AFTER EARLY SALVAGE RADIOTHERAPY IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2013, 189, .	0.2	2
342	Role of carbonic anhydrase <sc>IX</sc> (<sc>CAIX</sc>) in patients with renal cell carcinoma: can we currently assess its definitive value in prognosis, prediction to treatment response and diagnosis, and as a therapeutic approach?. <i>BJU International</i> , 2013, 111, 1015-1017.	1.3	2

#	ARTICLE	IF	CITATIONS
343	It is time to start active treatment in senior adults with prostate cancer. <i>Future Oncology</i> , 2014, 10, 5-8.	1.1	2
344	Does Multimedia Education with 3D Animation Impact Quality and Duration of Urologists's™ Interactions with their Prostate Cancer Patients?. <i>Advances in Therapy</i> , 2015, 32, 863-873.	1.3	2
345	PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	2
346	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. <i>European Urology Open Science</i> , 2020, 19, 16-19.	0.2	2
347	Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?. <i>European Urology Focus</i> , 2021, 7, 807-811.	1.6	2
348	Safety and efficacy of embolotherapy for severe hemorrhage after partial nephrectomy. <i>Acta Radiologica</i> , 2020, 61, 1701-1707.	0.5	2
349	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	2.6	2
350	Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy. <i>International Journal of Urology</i> , 2021, 28, 390-395.	0.5	2
351	A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 94-94.	0.8	2
352	Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. <i>Future Oncology</i> , 2020, 16, 2035-2044.	1.1	2
353	Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan. <i>Central European Journal of Urology</i> , 2019, 72, 232-239.	0.2	2
354	Prognostic score predicts overall survival following complete urinary tract extirpation. <i>Scandinavian Journal of Urology</i> , 2020, 54, 70-79.	0.6	2
355	Uro-oncology in the era of social distancing: the principles of patient-centered online consultations during the COVID-19 pandemic. <i>Central European Journal of Urology</i> , 2020, 73, 260-264.	0.2	2
356	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2022, 40, 54-57.	0.2	2
357	Surgery alone for advanced prostate cancer?. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 157-169.	2.2	1
358	795 EVALUATION OF CHOLINE (CHOL) PET CT AND DIFFUSION WEIGHTED (DW) MRI FOR THE NODAL STAGING OF PROSTATE CANCER (PCA) WITH A HIGH RISK OF LYMPH NODE (LN) METASTASES. <i>European Urology Supplements</i> , 2009, 8, 319.	0.1	1
359	64 POSTOPERATIVE MORBIDITY OF CLOSURE VERSUS NON-CLOSURE OF THE BUCCAL MUCOSA HARVEST SITE. <i>Journal of Urology</i> , 2010, 183, .	0.2	1
360	Is Radical Nephroureterectomy and Lymph Node Dissection Necessary for Upper-tract TCC?. <i>European Urology Supplements</i> , 2010, 9, 442-445.	0.1	1

#	ARTICLE	IF	CITATIONS
361	291 IN HIGH-RISK PROSTATE CANCER, A PELVIC LYMPH NODE DISSECTION WITH >20 LYMPH NODES REMOVED AT RADICAL PROSTATECTOMY SIGNIFICANTLY IMPROVES OVERALL SURVIVAL. <i>Journal of Urology</i> , 2011, 185, .	0.2	1
362	660 RRP AS STAND-ALONE THERAPY FOR HIGH-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2011, 185, .	0.2	1
363	The Use of Buccal Mucosa in Bulbar Stricture Repair: Morbidity and Functional Outcome. , 0, , .		1
364	Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2011;59:572-83. <i>European Urology</i> , 2011, 60, e39-e41.	0.9	1
365	Re: Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. <i>European Urology</i> , 2011, 60, 1121-1122.	0.9	1
366	Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos™ Letter to the Editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057 . <i>European Urology</i> , 2013, 63, e21-e22.	0.9	1
367	Management of Superficial Bladder Cancer in Elderly Patients. , 2013, , 231-245.		1
368	961 PREDICTORS OF EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN MEN WITH PT3NO PROSTATE CANCER. IMPLICATIONS FOR MULTI-MODAL THERAPIES. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
369	1697 PROGNOSTIC FACTORS AND RISK GROUPS IN T1G3 PATIENTS INITIALLY TREATED WITH BCG: RESULTS OF A MULTICENTER RETROSPECTIVE SERIES IN 2530 PATIENTS. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
370	Prediction of node-negative status after radical prostatectomy. <i>Nature Reviews Urology</i> , 2013, 10, 627-628.	1.9	1
371	Minimally invasive vs open radical prostatectomy in high-risk prostate cancer: comparing apples and pears?. <i>BJU International</i> , 2013, 112, 711-712.	1.3	1
372	MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL ON CANCER CONTROL AFTER EARLY SALVAGE RADIATION THERAPY POST RADICAL PROSTATECTOMY: NEED FOR PATIENT STRATIFICATION ACCORDING TO PROSTATE CANCER FEATURES. <i>Journal of Urology</i> , 2015, 193, .	0.2	1
373	Phase III randomised chemoprevention study of Selenium on the recurrence of non-invasive bladder cancer. The SELEnium and BLadder cancer Trial (SELEBLAT). <i>Archives of Public Health</i> , 2015, 73, .	1.0	1
374	Predicting Clinical Outcome Following Post Prostatectomy Radiation Therapy: A Poisson-Based Tumor Control Probability (TCP) Model Based on a Large Multi-institutional Series. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S53.	0.4	1
375	PD72-06 ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: A LONG-TERM SURVIVAL ANALYSIS. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
376	PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
377	Defining "High Risk" for Men with Localized Prostate Cancer: How Close Can Clinical Parameters Get Us?. <i>European Urology Oncology</i> , 2018, 1, 149-150.	2.6	1
378	Salvage prostatectomy for recurrent disease. <i>Nature Reviews Urology</i> , 2019, 16, 150-151.	1.9	1

#	ARTICLE	IF	CITATIONS
379	PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment. <i>BMC Medicine</i> , 2020, 18, 213.	2.3	1
380	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. <i>Acta Oncol</i> , 2020, 59, 904-910.	0.8	1
381	The 2014 ISUP grade group system: the Holy Grail or yet another hype?. <i>World Journal of Urology</i> , 2021, 39, 1315-1316.	1.2	1
382	Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.11.040 . <i>European Urology</i> , 2021, 79, e154-e156.	0.9	1
383	In Regard to Zelefsky et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 910-911.	0.4	1
384	Active Surveillance and Focal Therapy: A European Perspective. , 2013, , 37-52.		1
385	A phase 2 study of ^{99m} Tc-trofolostat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16003-e16003.	0.8	1
386	A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 261-261.	0.8	1
387	Obesity and prostate cancer research. <i>Central European Journal of Urology</i> , 2013, 66, 428-9.	0.2	1
388	1305 POSTER SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 175.	2.2	0
389	4022 POSTER The relationship between age and cancer related outcomes in clinical unilateral T3a prostate cancer. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 286.	2.2	0
390	739 THE USE OF THE IIEF-5 QUESTIONNAIRE FOR EVALUATION OF ERECTILE DYSFUNCTION FOLLOWING NERVE-SPARING RADICAL PROSTATECTOMY. <i>European Urology Supplements</i> , 2007, 6, 207.	0.1	0
391	Editorial Comment on: Predictive Factors for Progression in Patients with Clinical Stage T1a Prostate Cancer in the PSA Era. <i>European Urology</i> , 2008, 53, 362.	0.9	0
392	PSA DENSITY IS A STRONGER PROGNOSTIC FACTOR THAN PSA FOR ADVERSE FINAL HISTOPATHOLOGIC OUTCOMES AND BIOCHEMICAL PROGRESSION FREE SURVIVAL IN CT3A PROSTATE CANCER. <i>European Urology Supplements</i> , 2008, 7, 153.	0.1	0
393	POD-2.06: Organ-Preserving Surgery for Penile Cancer. <i>Urology</i> , 2008, 72, S34-S35.	0.5	0
394	POSITIVE SURGICAL MARGINS APPEAR TO HAVE NEGLIGIBLE IMPACT ON THE SURVIVAL OF RENAL CELL CARCINOMAS TREATED BY NEPHRON SPARING SURGERY. <i>Journal of Urology</i> , 2008, 179, 416-417.	0.2	0
395	A patient support programme to improve quality of life in patients with prostate cancer treated with LH-RH agonists. <i>Journal of Men's Health</i> , 2009, 6, 265-265.	0.1	0
396	Editorial Comment on: Phase One Pilot Study Using Magnetic Resonance Spectroscopy to Predict the Histology of Radiofrequency-Ablated Renal Tissue. <i>European Urology</i> , 2009, 55, 438-439.	0.9	0

#	ARTICLE	IF	CITATIONS
397	POD-05.07: Radical Prostatectomy for Prostate Cancer with PSA >100 ng/ml. Urology, 2009, 74, S15-S16.	0.5	0
398	UP-2.088: Contribution of PET-CT in the Diagnosis of Transitional Cell Carcinoma of the Upper Urinary Tract: Analysis of 20 Cases. Urology, 2009, 74, S258.	0.5	0
399	UP-2.120: Determining Under- and Over-Grading by Biopsy Gleason Score in Clinical T3 Prostate Cancer. Urology, 2009, 74, S268-S269.	0.5	0
400	UP-1.066: Results of RFA in Patients with Small Renal Masses: A Single-Centre Experience with Median Follow-Up of 48 Months. Urology, 2009, 74, S190-S191.	0.5	0
401	526 OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA >20 NG/ML) : A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS. European Urology Supplements, 2009, 8, 252.	0.1	0
402	614 THE IMPORTANCE OF POSITIVE SECTION MARGINS IN PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY. European Urology Supplements, 2009, 8, 274.	0.1	0
403	OUTCOME OF MULTIMODALITY TREATMENT WITH RADICAL PROSTATECTOMY AS INITIAL STEP FOR PROSTATE CANCER WITH PSA >20 NG/ML : A MULTI-INSTITUTIONAL OUTCOME STUDY OF 801 PATIENTS. Journal of Urology, 2009, 181, 456-456.	0.2	0
404	7000 A multi-institutional analysis comparing adjuvant and salvage postoperative radiation therapy for prostate cancer patients with undetectable PSA and high-risk features in the prostatectomy specimen. European Journal of Cancer, Supplement, 2009, 7, 405.	2.2	0
405	OUTCOME OF MULTIMODALITY TREATMENT OF HIGH-RISK LOCALIZED PROSTATE CANCER (CT3-4 OR PSA >20 NG/ML) : A MULTI-INSTITUTIONAL OUTCOME STUDY OF 1413 PATIENTS. Journal of Urology, 2009, 181, 574-575.	0.2	0
406	624 YEAR OF RADICAL PROSTATECTOMY IS AN INDEPENDENT SIGNIFICANT PREDICTOR OF BIOCHEMICAL AND CLINICAL PROGRESSION IN CLINICAL T3 PROSTATE CANCER. European Urology Supplements, 2009, 8, 276.	0.1	0
407	91 poster: Investigating the Impact of the Highly Variable Lymphatic Drainage Pattern in Prostate Cancer Patients. Radiotherapy and Oncology, 2010, 94, S35.	0.3	0
408	œLuproCareœ: A patient support programme to improve quality of life in patients with prostate cancer treated with LHRH agonists. Journal of Men's Health, 2010, 7, 333-333.	0.1	0
409	Reply to Endre Zoltan Neulander and Zev Wejsman's Letter to the Editor re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. Eur Urol 2010;58:1-7. European Urology, 2010, 58, e37-e38.	0.9	0
410	63 SINGLE-STAGE SALVAGE URETHROPLASTY AFTER PREVIOUS OPEN SURGERY. Journal of Urology, 2010, 183, .	0.2	0
411	61 END-TO-END REPAIR OR BUCCAL MUCOSA GRAFT FOR SINGLE-STAGE BULBAR URETHROPLASTY?. Journal of Urology, 2010, 183, .	0.2	0
412	1207 GOOD CLINICAL OUTCOME AFTER URETHROPLASTY AT THE EXPENSE OF ERECTILE FUNCTION LOSS?. Journal of Urology, 2010, 183, .	0.2	0
413	578 PREDICTING PROSTATE CANCER SPECIFIC OUTCOME AFTER RADICAL PROSTATECTOMY AMONG MEN WITH PSA &[GE] 20 NG/ML WITH OR WITHOUT ADDITIONAL HIGH RISK FACTORS: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 712 PATIENTS. Journal of Urology, 2010, 183, .	0.2	0
414	2030 HIGH-RISK PROSTATE CANCER PATIENTS WHO HAVE SPECIMEN-CONFINED DISEASE AT PATHOLOGY HAVE EXCEPTIONALLY GOOD OUTCOMES AFTER SURGERY. Journal of Urology, 2010, 183, .	0.2	0

#	ARTICLE	IF	CITATIONS
415	1552 PREDICTING FAVOURABLE PATHOLOGICAL OUTCOME IN PATIENTS WITH CLINICAL HIGH RISK PROSTATE CANCER. A NOVEL NOMOGRAM BASED ON A MULTI-INSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
416	1061 VALUE OF ELND IN LYMPH NODE NEGATIVE PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER IS UNCERTAIN. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
417	1065 PREDICTORS OF ONCOLOGIC OUTCOMES AFTER SALVAGE RADICAL PROSTATECTOMY FOR RADIO-RECURRENT PROSTATE CANCER: A MULTI-INSTITUTIONAL COLLABORATION. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
418	683 THE ROLE OF POSITIVE SECTION MARGINS IN PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY: PROSPECTIVE ANALYSIS OF 566 PATIENTS. <i>European Urology Supplements</i> , 2010, 9, 224.	0.1	0
419	UP-2.72: Urethroplasty in multiple stages using buccal mucosa grafts. <i>Urology</i> , 2010, 76, S104-S105.	0.5	0
420	Adjuvant and Salvage Radiation for Advanced Prostate Cancer: A Discussion During the ESOU 2010 Meeting. <i>European Urology Supplements</i> , 2010, 9, 401-405.	0.1	0
421	1063 TIME TO BIOCHEMICAL RECURRENCE IS A STRONG AND INDEPENDENT PREDICTOR OF CSS AND OS IN HIGH-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
422	699 THE PROGNOSTIC SIGNIFICANCE OF TUMOR DIAMETER IN INCIDENTALLY DETECTED SMALL RENAL MASSES. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
423	1630 MICRO-RNA-221 IS A STRONG AND INDEPENDENT PREDICTOR OF CLINICAL PROGRESSION AND CSS IN HIGH-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
424	1048 DEVELOPMENT AND INTERNAL VALIDATION OF NOMOGRAMS PREDICTING PROSTATE CANCER SPECIFIC SURVIVAL IN PATIENTS WITH HIGH RISK DISEASE. RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. <i>European Urology Supplements</i> , 2011, 10, 324.	0.1	0
425	1763 SURVIVAL IMPACT OF SURGERY IN METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
426	1790 OUTCOME OF MULTIMODALITY TREATMENT OF VERY HIGH-RISK T4-PROSTATE CANCER WITH RADICAL CYSTECTOMY AS INITIAL STEP. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
427	480 IN HIGH-RISK PROSTATE CANCER, AGE, BUT NOT CHARLSON SCORE IS A MAJOR PREDICTOR OF OVERALL SURVIVAL. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
428	1082 THE EFFECTS OF PREVIOUS PREPERITONEAL INGUINAL HERNIA REPAIR ON OPERATIVE AND FUNCTIONAL OUTCOMES OF OPEN, RETROPUBLIC RADICAL PROSTATECTOMY: A CASE-MATCHED ANALYSIS. <i>European Urology Supplements</i> , 2011, 10, 333.	0.1	0
429	1474 PT3-PROSTATE CANCER-POSITIVE SURGICAL MARGIN AT BLADDER NECK IS AN INDEPENDANT PREDICTOR OF LOCAL FAILURE AND PROSTATE CANCER MORTALITY: RESULTS OF A PROSPECTIVE SINGLE INSTITUTION SERIES. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
430	1046 THREE OR MORE POSITIVE NODES AT RADICAL PROSTATECTOMY REPRESENT A SIGNIFICANT CUT-OFF VALUE FOR CSS IN HIGH-RISK PROSTATE CANCER, WHILE 1 OR 2 POSITIVE NODES DO NOT INFLUENCE CSS. <i>European Urology Supplements</i> , 2011, 10, 323.	0.1	0
431	563 IN HIGH-RISK PROSTATE CANCER, THE NUMBER OF LYMPH NODES REMOVED AT RADICAL PROSTATECTOMY DOES NOT AFFECT THE RISK OF CANCER RELATED DEATH OR DEATH FROM ANY CAUSE. <i>European Urology Supplements</i> , 2011, 10, 185-186.	0.1	0
432	675 TIME TO BIOCHEMICAL RECURRENCE IS A STRONG AND INDEPENDENT PREDICTOR OF CSS AND OS IN HIGH-RISK PROSTATE CANCER. <i>European Urology Supplements</i> , 2011, 10, 217.	0.1	0

#	ARTICLE	IF	CITATIONS
433	749 DOWNREGULATION OF MIR-221 IS A STRONG AND INDEPENDENT PREDICTOR OF CLINICAL PROGRESSION AND CSS IN HIGH-RISK PROSTATE CANCER. <i>European Urology Supplements</i> , 2011, 10, 238-239.	0.1	0
434	907 THE NUMBER OF POSITIVE SECTION MARGINS IN HIGH-RISK PROSTATE CANCER IS A POWERFUL AND INDEPENDENT PREDICTOR OF CANCER-SPECIFIC AND OVERALL SURVIVAL IN HIGH-RISK LOCALIZED PROSTATE CANCER. <i>European Urology Supplements</i> , 2011, 10, 285.	0.1	0
435	322 oral MULTI-MODALITY MR IMAGING FOR PROSTATE CANCER DETECTION IN CORRELATION TO WHOLE-MOUNT HISTOPATHOLOGY. <i>Radiotherapy and Oncology</i> , 2011, 99, S129.	0.3	0
436	294 IN HIGH-RISK PROSTATE CANCER, 3 OR MORE POSITIVE NODES AT RADICAL PROSTATECTOMY REPRESENT AN INDEPENDENT PREDICTOR OF WORSE CSS, WHILE 1 OR 2 POSITIVE NODES DO NOT INFLUENCE CSS. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
437	UP-03.140 Endoscopic Laser Therapy as Alternative for Nephroureterectomy in Patients with Upper Urinary Tract Transitional Cell Carcinoma. <i>Urology</i> , 2011, 78, S390.	0.5	0
438	MP-12.03 Management of Iatrogenic Rectourinary Fistulas: A Six-Year Experience. <i>Urology</i> , 2011, 78, S116-S117.	0.5	0
439	469 ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY IN LOCALLY ADVANCED PROSTATE CANCER: A MULTI-CENTER EXPERIENCE. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
440	Introduction. <i>Acta OncolÃ³gica</i> , 2011, 50, 24-24.	0.8	0
441	Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel. <i>Clinical Investigation</i> , 2012, 2, 995-1002.	0.0	0
442	936 THE IMPACT OF AGE AND COMORBIDITIES ON SURVIVAL AFTER RADICAL PROSTATECTOMY IN HIGH-RISK PROSTATE CANCER PATIENTS: A COMPETING-RISKS ANALYSIS. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
443	998 HIGH-RISK PROSTATE CANCER PRESENTING WITH BIOPSY GLEASON SCORE 8, 9 OR 10: DOWNGRADING AND CANCER-SPECIFIC SURVIVAL. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
444	258 IDENTIFICATION OF TELOCYTES IN THE UPPER LAMINA PROPRIA OF THE HUMAN. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
445	363 STRATIFICATION OF HIGH-RISK PROSTATE CANCER INTO PROGNOSTIC CATEGORIES; A EUROPEAN MULTI-INSTITUTIONAL STUDY. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
446	1116 RADICAL PROSTATECTOMY FOR VERY HIGH RISK T3B/4 PROSTATE CANCER â€“ LONG TERM RESULTS OF A MULTIINSTITUTIONAL EXPERIENCE. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
447	1790 CLINICAL RISK CLASSIFICATION SCORE IN PATIENTS AMENABLE FOR METASTASECTOMY FROM ADVANCED RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
448	1122 DEVELOPMENT OF A NOVEL PREOPERATIVE NOMOGRAM INCLUDING THE BIOMARKER MICRO-RNA 221 - PREDICTING CANCER SPECIFIC MORTALITY IN HIGH RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
449	2230 VALIDATION OF THE NEW BIOMARKER MICRO-RNA-221 TO PREDICT CANCER RELATED DEATH IN HIGH-RISK PROSTATE CARCINOMA - RESULTS OF A METAANALYSIS. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
450	2226 LET-7B IS DOWN-REGULATED IN HIGH RISK PROSTATE CANCER AND AN INDEPENDENT PREDICTOR FOR CLINICAL FAILURE. <i>Journal of Urology</i> , 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
451	Robot-assisted partial nephrectomy in patients with recurrent disease: fiction or fact?. BJU International, 2013, 111, 692-694.	1.3	0
452	Re: Axel Heidenreich, David Pfister. Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care. Eur Urol 2012;62:1201-4. European Urology, 2013, 64, e62-e64.	0.9	0
453	773 IS THERE A ROLE FOR SALVAGE EXTENDED LYMPH NODE DISSECTION FOR PATIENTS WITH NODAL RECURRENCE OF PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY? RESULTS BASED ON A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2013, 189, .	0.2	0
454	776 ASSOCIATION BETWEEN TIME TO BIOCHEMICAL RECURRENCE AND CANCER SPECIFIC AND OTHER CAUSE MORTALITY IN MEN WITH HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY WITHOUT ADJUVANT TREATMENTS. A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2013, 189, .	0.2	0
455	788 SUBGLANDULAR INTERSTITIAL CELLS IN NORMAL HUMAN PROSTATE AND DISEASE-RELATED CHANGES IN BENIGN PROSTATE HYPERTROPHY AND PROSTATE CARCINOMA. Journal of Urology, 2013, 189, .	0.2	0
456	Reply to Kwang Hyun Kim and Koon Ho Rha's Letter to the Editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. Eur Urol 2013;63:450-8. European Urology, 2013, 64, e57-e58.	0.9	0
457	OP3-06 IMPACT OF TIME TO BIOCHEMICAL RECURRENCE ON CANCER-SPECIFIC MORTALITY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
458	MP42-13 RISK STRATIFICATION AMONG MEN UNDERGOING RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER IN U.S. COHORT: AN EMPACT STUDY. Journal of Urology, 2014, 191, .	0.2	0
459	MP78-05 CHANGING TRENDS IN THE CLINICAL PRESENTATION OF HIGH-RISK PROSTATE CANCER OVER THE LAST 22 YEARS.. Journal of Urology, 2014, 191, .	0.2	0
460	MP42-04 MAPPING OF TRUE POSITIVE, FALSE POSITIVE AND FALSE NEGATIVE LYMPH NODES AFTER SALVAGE LYMPH NODE DISSECTION IN PROSTATE CANCER PATIENTS WITH POSITIVE NODES AT 11C CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY. Journal of Urology, 2014, 191, .	0.2	0
461	MP45-04 PREDICTING PROSTATE CANCER SPECIFIC OUTCOME AFTER RADICAL PROSTATECTOMY AMONG MEN WITH CT3B/4 PCA WITH OR WITHOUT ADDITIONAL HIGH RISK FACTORS: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 266 PATIENTS. Journal of Urology, 2014, 191, .	0.2	0
462	MP5-08 WHEN WE RECOMMEND A CONSERVATIVE MANAGEMENT FOR URETEROINTESTINAL STRICTURES FOLLOWING RADICAL CYSTECTOMY WITH ILEAL CONDUIT.. Journal of Urology, 2014, 191, .	0.2	0
463	PD27-08 PREDICTORS OF EARLY FAILURE AFTER TIMELY ADMINISTERED SALVAGE RADIOTHERAPY FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
464	MP42-20 MAPPING OF PELVIC LYMPH NODES AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION INCLUDING PRE-SACRAL AND COMMON ILIAC REGIONS. Journal of Urology, 2014, 191, .	0.2	0
465	MP56-16 THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.. Journal of Urology, 2014, 191, .	0.2	0
466	MP27-19 QUALITY OF LIFE AND FUNCTIONAL RESULTS AFTER ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A PROSPECTIVE POPULATION-BASED SERIES. Journal of Urology, 2015, 193, .	0.2	0
467	MP53-07 NEED FOR A SURGICAL TEMPLATE IN SALVAGE LYMPHADENECTOMY FOR NODAL RECURRENCE OF PROSTATE CANCER: IS PELVIC INVOLVEMENT PREDICTIVE OF RETROPERITONEAL POSITIVITY?. Journal of Urology, 2015, 193, .	0.2	0
468	MP56-10 LONG-TERM SURVIVAL PATTERNS OF YOUNG PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY. RESULTS OF A MULTI INSTITUTIONAL, CONDITIONAL SURVIVAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0

#	ARTICLE	IF	CITATIONS
469	PD32-08 CHOLINE PET/CT SCAN FOR THE DETECTION OF NODAL RELAPSES OF PROSTATE CANCER AFTER BIOCHEMICAL RECURRENCE: RESULTS FROM A MULTICENTRIC STUDY. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
470	MP77-03 GLEASON SCORE UPGRADING TO 8-10 PREDICTS BIOCHEMICAL RECURRENCE IN MEN UNDERGOING RADICAL PROSTATECTOMY: ANALYSIS ON 7310 HIGH-RISK PATIENTS FROM THE EMPACT DATABASE.. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
471	MP19-18 INTRATUNICAL INJECTION OF ADIPOSE STROMAL VASCULAR FRACTION (SVF) PREVENTS FIBROSIS EXPRESSION IN A RAT MODEL OF PEYRONIE'S DISEASE. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
472	MP19-16 HUMAN ADIPOSE TISSUE DERIVED STEM CELLS (HADSCS) PREVENTS FIBROSIS AND BLADDER DYSFUNCTION IN A RAT MODEL OF URETHRAL STRICTURE. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
473	MP82-01 LONG-TERM OUTCOMES OF VERY HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT TREATMENTS. RESULTS OF A COMPETING RISKS, MULTI INSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
474	MP9-20 BASELINE CLINICAL CARACTERISTICS AND PATHOLOGICAL OUTCOMES FOLLOWING ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A POPULATION BASED PROSPECTIVE SERIES.. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
475	PD17-11 THE IMPACT OF DIFFERENT BCG STRAINS ON OUTCOME IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
476	MP15-16 REVISION URETHROPLASTY VS PRIMARY URETHROPLASTY: ARE THEY REALLY DIFFERENT?. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
477	PD2-05 IDIOPATHIC PARTIAL THROMBOSIS IS ASSOCIATED WITH CYCLING AND THE PRESENCE OF A FIBROUS WEB ON MRI. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
478	PD37-06 CAN WE PREDICT LATE RECURRENCES AFTER RADICAL PROSTATECTOMY IN MEN WITH HIGH RISK PROSTATE CANCER? A VERY LONG TERM ANALYSIS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
479	MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
480	MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3N0 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
481	MP50-03 SALVAGE RADICAL PROSTATECTOMY COMPLICATIONS AND FUNCTIONAL OUTCOMES: OPEN VERSUS ROBOTIC PROCEDURES.. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
482	MP69-06 THE ROLE OF EXTENDED OR SUPER-EXTENDED LYMPH NODE DISSECTION FOR STAGING OF HIGH-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
483	MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
484	Learning to Fly. <i>European Urology</i> , 2016, 69, 691-692.	0.9	0
485	PD48-07 COMPARISON OF PERCUTANEOUS RADIOFREQUENCY ABLATION AND PARTIAL NEPHRECTOMY FOR TREATING T1A RCC IN SOLITARY KIDNEY PATIENTS. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
486	PO-0870: Fitting data of relapse-free survival after postprostatectomy RT with a comprehensive TCP model. <i>Radiotherapy and Oncology</i> , 2016, 119, S416.	0.3	0

#	ARTICLE	IF	CITATIONS
487	PD37-11 FUNCTIONAL OUTCOMES AFTER EXTENDED VS. SUPER-EXTENDED PELVIC LYMPH NODE DISSECTION FOR INTERMEDIATE AND HIGH-RISK LOCALIZED PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
488	MP09-09 HISTORICAL TRENDS IN HIGH-RISK PROSTATE CANCER PATIENTS CHARACTERISTICS: A 27 YEARS OLD OBSERVATIONAL STUDY FROM A MULTICENTER PROSTATE CANCER CLINICAL AND TRANSLATIONAL RESEARCH GROUP. Journal of Urology, 2016, 195, .	0.2	0
489	PD12-12 COMPLICATION RATES AFTER RADICAL CYSTECTOMY AFTER RADIOTHERAPY: AN INTERNATIONAL, MULTICENTER RETROSPECTIVE STUDY ON 609 CASES. Journal of Urology, 2016, 195, .	0.2	0
490	MP64-02 ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY: A MULTICENTRE SERIES OF 243 PATIENTS. Journal of Urology, 2017, 197, .	0.2	0
491	PD48-07 RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT. Journal of Urology, 2017, 197, .	0.2	0
492	MP77-01 11C-CHOLINE VERSUS 68GA-PSMA PET/CT SCAN FOR THE DETECTION OF NODAL RECURRENCE FROM PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SALVAGE LYMPH NODE DISSECTION SERIES. Journal of Urology, 2017, 197, .	0.2	0
493	MP93-02 COMPARISON OF ONCOLOGICAL OUTCOMES BETWEEN OPEN VERSUS ROBOT-ASSISTED SALVAGE RADICAL PROSTATECTOMY: A RETROSPECTIVE MULTICENTRE SERIES. Journal of Urology, 2017, 197, .	0.2	0
494	PD51-08 ASSESSING THE 20-YEAR OUTCOMES OF RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2017, 197, .	0.2	0
495	PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
496	MP46-01 IS THE ICIQ-SF QUESTIONNAIRE RELIABLE IN A REAL-LIFE SETTING? RESULTS OF A PROSPECTIVE SINGLE-CENTER STUDY. Journal of Urology, 2017, 197, .	0.2	0
497	PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
498	PD72-05 NATURAL HISTORY OF PATIENTS TREATED WITH SALVAGE RADIATION THERAPY FOR RISING PSA AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
499	PD15-09 IDENTIFYING THE OPTIMAL CANDIDATE FOR SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
500	PD15-11 MORE EXTENSIVE LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER SALVAGE RADIOTHERAPY FOR RISING PSA AFTER SURGERY: A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
501	Two-Stage Urethroplasty with Buccal Mucosa for Penoscrotal Hypospadias Reconstruction in a Male with a 46,XX Karyotype. Urology Case Reports, 2017, 14, 45-47.	0.1	0
502	Multimodality treatment for pN1 prostate cancer: Adding elective para-aortic radiation in the PART trial. Annals of Oncology, 2018, 29, viii302.	0.6	0
503	OC-0160 When PI-RADS and ISUP meet each other: identification of candidates for pelvic lymph node dissection. Radiotherapy and Oncology, 2019, 133, S77-S78.	0.3	0
504	Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. European Urology, 2019, 76, 537-539.	0.9	0

#	ARTICLE	IF	CITATIONS
505	Genomic analysis of localized prostate cancer identifies AZIN1 as driver of metastatic progression. <i>European Urology Open Science</i> , 2020, 19, e1669.	0.2	0
506	Male Wolffian adnexal tumor: the first report of long-term follow-up after radical surgical treatment. <i>Current Urology</i> , 2021, 15, 126-128.	0.4	0
507	Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 7.e9-7.e17.	0.8	0
508	Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 473-478.	0.2	0
509	Is the Age of Extended Pelvic Lymph Node Dissection Over? The Devil Is in the Details. <i>European Urology Oncology</i> , 2021, 4, 540-542.	2.6	0
510	Systemische therapie van prostaatkanker. Deel I: Hormonale therapie. <i>Tijdschrift Voor Geneeskunde</i> , 2004, 60, 1597-1606.	0.0	0
511	Systemische therapie voor prostaatkanker. Deel II: Niet-hormonale therapie. <i>Tijdschrift Voor Geneeskunde</i> , 2004, 60, 1673-1680.	0.0	0
512	Immunotherapie voor het gemetastaseerde niercelcarcinoom. <i>Tijdschrift Voor Geneeskunde</i> , 2005, 61, 1044-1052.	0.0	0
513	Open Surgery for Localized RCC. <i>TSW Urology</i> , 2007, 2, 16-26.	0.1	0
514	Indications for radical prostatectomy. , 2007, , 23-37.		0
515	Salvage reconstructive surgery in an adult patient with failed previous repair of an extrophy-epispadias complex: an operation with a functional and aesthetic purpose. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2007, 33, 810-814.	0.7	0
516	Does Body Mass Index Influence the Outcomes After Surgery for Locally Advanced Prostate Cancer?. <i>The Open Prostate Cancer Journal</i> , 2009, 2, 10-15.	0.4	0
517	Radical Prostatectomy for Locally Advanced Prostate Cancer. , 2009, , 281-288.		0
518	The Role of Nephron-Sparing Surgery (NSS) for Renal Tumours >4 cm. , 0, , .		0
519	Expression of PRAME and MAGE-A3 in Asian and European patients with non-small cell lung cancer (NSCLC), bladder cancer, or hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13061-e13061.	0.8	0
520	Methylation-guided stratification of patients with high-risk prostate cancer for the prediction of clinical failure.. <i>Journal of Clinical Oncology</i> , 2014, 32, 155-155.	0.8	0
521	The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-114.	0.8	0
522	The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 140-140.	0.8	0

#	ARTICLE	IF	CITATIONS
523	Comparing Single-Item Assessment and IIEF-5 for Reporting Erectile Dysfunction Following Nerve-Sparing Radical Retropubic Prostatectomy. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 13-21.	0.2	0
524	Technical Aspects of Focal Therapy in Localized Prostate Cancer: Follow-Up After Focal Therapy. , 2015, , 199-208.		0
525	Charlson score to predict overall survival and cancer-related death in elderly patients featuring high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 84-84.	0.8	0
526	Metastases-prone localized prostate cancer: a genomic analysis. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
527	Open Radical Prostatectomy. , 2017, , 171-180.		0
528	Chemoprevention. , 2017, , 29-41.		0
529	Re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9â€“10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>Eur Urol</i> 2017;71:766â€“73. <i>European Urology</i> , 2017, 72, e121-e122.	0.9	0
530	Abstract B075: The role of TET1 and hydroxymethylation in high-risk prostate cancer. , 2018, , .		0
531	Nine-year survival after iterative metastasectomies for renal cell carcinoma. <i>Urology Annals</i> , 2019, 11, 219.	0.3	0
532	PD51-09â€“fTHE CANCER OF THE BLADDER RISK ASSESSMENT (COBRA) SCORE FOR ESTIMATING CANCER-SPECIFIC SURVIVAL AFTER RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2020, 203, e1086.	0.2	0
533	MP75-04â€“fHIGH RISK CLASSIFICATION ACROSS GUIDELINES (NCCN VS. EAU). <i>Journal of Urology</i> , 2020, 203, e1142-e1143.	0.2	0
534	MP79-02â€“fPERFORMANCE CHARACTERISTICS OF PET/CT SCAN IN MEN TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER: A PER PATIENT ANALYSIS WITH PATHOLOGICAL CONFIRMATION ACCORDING TO EACH AREA OF DISSECTION. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
535	MP74-02â€“fLONG-TERM OUTCOMES OF CLINICALLY NODE-POSITIVE PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT: PATTERNS OF RECURRENCE AND IMPACT ON COMPETING-RISK MORTALITY. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
536	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.2	0
537	Time to change the management of upper urinary tract urothelial carcinoma. <i>Central European Journal of Urology</i> , 2020, 73, 381-382.	0.2	0
538	MP14-13â€“fTHE ROLE OF CYTOREDUCTIVE NEPHRECTOMY IN THE CONTEMPORARY MANAGEMENT OF METASTATIC KIDNEY CANCER: PREDICTIVE FACTORS FOR SURGICAL COMPLICATIONS AND ONCOLOGICAL SURVIVAL. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
539	MP82-06â€“fNEW CLASSIFICATION FOR UPPER TRACT UROTHELIAL CARCINOMA TO ENHANCE RISK STRATIFICATION OF PATIENTS ELIGIBLE TO ENDOSCOPIC MANAGEMENT: AN INTERNATIONAL COLLABORATIVE STUDY. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
540	MP37-16â€“fASSESSING THE IMPACT OF SALVAGE RADIATION THERAPY FIELD AFTER RADICAL PROSTATECTOMY: A LONG-TERM ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES. <i>Journal of Urology</i> , 2020, 203, .	0.2	0

#	ARTICLE	IF	CITATIONS
541	PD03-09â€fQUALITY CONTROL INDICATORS (QCIS) FOR TRANSURETHRAL RESECTIONS OF BLADDER TUMORS: CORRELATION OF QCIS WITH CLINICAL OUTCOME IN A BELGIAN MULTI-CENTER PROSPECTIVE REGISTRY. Journal of Urology, 2020, 203, .	0.2	0
542	MP37-11â€fASSOCIATION BETWEEN THE EXTENT OF LYMPH NODE DISSECTION AND SEVERE TOXICITY IN MEN WITH PROSTATE CANCER TREATED WITH POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	0.2	0
543	MP72-12â€fLUMINAL AND BASAL IMMUNOHISTOCHEMICAL MARKERS IN PAPILLARY PTA BLADDER CANCER: THE COUNTERINTUITIVE ROLE OF CK5. Journal of Urology, 2020, 203, .	0.2	0
544	PD43-04â€fSALVAGE RADICAL PROSTATECTOMY FOR RECURRENT PROSTATE CANCER: ONCOLOGICAL OUTCOMES OF A CONTEMPORARY MULTICENTER STUDY. Journal of Urology, 2020, 203, .	0.2	0
545	PD12-03â€fQUALITY CONTROL INDICATORS FOR TRANSURETHRAL RESECTIONS OF BLADDER TUMORS. Journal of Urology, 2020, 203, e260.	0.2	0
546	MP37-17â€fCHANGING PATTERNS AND PREDICTORS OF SALVAGE RADIATION THERAPY USE OVER TIME IN PATIENTS TREATED FOR POST-PROSTATECTOMY BIOCHEMICAL RECURRENCE: A TREND ANALYSIS OVER A 20-YEAR PERIOD FROM A MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2020, 203, .	0.2	0
547	MP40-04â€fANATOMICAL PROSTATE MPMRI FEATURES AND CONTINENCE RECOVERY AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY: IS THERE SOMETHING BEYOND MEMBRANOUS URETHRAL LENGTH? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL COHORT. Journal of Urology, 2020, 203, .	0.2	0
548	Focal Salvage Therapy for Prostate Cancer Recurrence After Primary Radiotherapy. , 2021, , 161-180.		0
549	Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment. , 2021, , 211-221.		0
550	Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer. European Urology, 2022, 81, 314-314.	0.9	0
551	Do we have enough evidence for approval of nadofaragene firadenovec?. Minerva Urology and Nephrology, 2022, , .	1.3	0
552	Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Cancers, 2022, 14, 1981.	1.7	0
553	Title is missing!. , 2020, 15, e0244663.		0
554	Title is missing!. , 2020, 15, e0244663.		0
555	Title is missing!. , 2020, 15, e0244663.		0
556	Title is missing!. , 2020, 15, e0244663.		0
557	Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate Cancer. European Urology Oncology, 2022, , .	2.6	0